美国Mersana Therapeutics
Mersana 是一家未公开上市的由风险投资做为后盾 (venture-backed) 的企业。该公司正在通过使用 Fleximer(R) 开发基于临床验证药物的新型抗肿瘤药剂。Fleximer(R) 是一种获得专利的生物可降解与生物惰性物质，能增强药物的药物代谢动力、安全性和溶解性。Mersana 拥有来自 Massachusetts General Hospital 对其核心技术的独家授权。Mersana 研发的产品系列中包含一些已经通过其专利技术而得到改进的复方药，这些复方药具有抗多种癌症的活性，并在人体实验中得到了证明。Mersana 的投资方包括 Fidelity Biosciences、ProQuest Investments、Rho Ventures、Harris & Harris Group 和 PureTech Ventures。

Fleximer 技术能通过把生物降解能力和“生物暗中作用”特性独特地结合起来，改善可有效用作抗癌药剂的细胞毒素复方药物的治疗指数，从而使 Fleximer(R) 物质与其共轭物体的具有长的循环周期且成为非免疫毒素疗法 (non-immunotoxic)。Fleximer 分子具有如下特点：可溶于水、在一般的生产过程和正常生理状态下很稳定，同时具有细胞摄入时不涉及酶作用的生物降解能力。


Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Our technology harnesses the power and synergy of nanotechnology, biologics and small molecules.

Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. Utilizing our technology, we are developing a portfolio of next-generation antibody-drug conjugates (ADC) with superior properties not found with current ADC technologies. Our clinical pipeline consists of two cancer therapeutics with blockbuster potential. XMT-1001 is a potentially best-in-class novel "tecan" conjugate that is currently being investigated in a Phase 1b extension trial in patients with lung cancers. XMT-1107 is a first-in-class anti-angiogenic conjugate with a unique mechanism of action that is currently in a Phase 1 trial in patients with refractory, advanced solid tumors. XMT-1107 was licensed to Teva on a worldwide basis except for Japan, where Mersana elected to retain rights. These clinical candidates reflect the successful application of our unique conjugation system.

This versatile conjugation system integrates Fleximer®, a clinically validated biodegradable polymer, with a broad array of customized linker chemistries designed to control conjugation, stability and release of diverse classes of therapeutic payloads. This system provides important benefits required for the development of next-generation drugs across therapeutic modalities, including ADCs, antibody fragments, small molecules, biologics and siRNA, as well as synergistic drug combinations. Mersana's approach results in completely novel drugs with intellectual property protection and extended patent life, via novel composition-of-matter.

Our technology is being leveraged in multiple therapeutic areas through partnerships. Mersana is interested in pursuing technology-enabling and proprietary drug candidate-based opportunities with partners interested in accessing our cutting-edge, clinically validated drug conjugation system.